Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention.

Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst (2008) 2.17

Renal cell carcinoma. Cancer Biomark (2010) 1.56

Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer (2003) 1.05

Changes in clinicopathological characteristics of renal cell carcinoma in the past 25 years: a single-center experience. Korean J Urol (2011) 1.02

No association between fruit, vegetables, antioxidant nutrients and risk of renal cell carcinoma. Int J Cancer (2010) 0.98

ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. BMC Cancer (2008) 0.96

Reliability of serum iron, ferritin, nitrite, and association with risk of renal cancer in women. Cancer Detect Prev (2003) 0.93

Case-control analysis of nucleotide excision repair pathway and the risk of renal cell carcinoma. Carcinogenesis (2008) 0.86

Sensitivity to NNKOAc is associated with renal cancer risk. Carcinogenesis (2009) 0.85

Lifestyle issues and genitourinary tumours. World J Urol (2003) 0.82

Cruciferous vegetables intake is associated with lower risk of renal cell carcinoma: evidence from a meta-analysis of observational studies. PLoS One (2013) 0.82

Polymorphisms in genes related to activation or detoxification of carcinogens might interact with smoking to increase renal cancer risk: results from The Netherlands Cohort Study on diet and cancer. World J Urol (2007) 0.77

Effects of open versus laparoscopic nephrectomy techniques on oxidative stress markers in patients with renal cell carcinoma. Oxid Med Cell Longev (2013) 0.77

Association between cadmium exposure and renal cancer risk: a meta-analysis of observational studies. Sci Rep (2015) 0.76

The association between fish consumption and risk of renal cancer: a meta-analysis of observational studies. PLoS One (2013) 0.75

Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention. BJU Int (2001) 0.75

[Renal cell carcinoma]. Urologe A (2006) 0.75

[Castleman's disease and chromophobe carcinoma of the kidney. An incidental association?]. Ann Pathol (1998) 1.42

[Low pressure bladder replacement after total cysto-prostatectomy. Apropos of a series of 40 patients]. J Urol (Paris) (1991) 1.39

Knowledge, attitudes and vaccination coverage of healthcare workers regarding occupational vaccinations. Vaccine (2009) 1.38

Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer (1995) 1.25

Within 1 h, HIV-1 uses viral synapses to enter efficiently the inner, but not outer, foreskin mucosa and engages Langerhans-T cell conjugates. Mucosal Immunol (2010) 1.17

Bisulfite genomic sequencing of microdissected cells. Nucleic Acids Res (2001) 1.14

Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int J Cancer (1999) 1.11

High incidence of brain metastases in patients treated with an M-VAC regimen for advanced bladder cancer. Eur Urol (1998) 1.11

Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines. J Clin Endocrinol Metab (2010) 1.11

Knotting of a double pigtail stent within the ureter: an initial report. J Urol (1995) 1.09

Imaging in male hypofertility and impotence. BJU Int (2000) 1.08

Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer (2006) 1.08

Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw (2000) 1.06

Risk factors for adult renal cell carcinoma. Urol Clin North Am (2004) 1.06

Systemic bacillus Calmette-Guérin infection, 'BCGitis', in patients treated by intravesical bacillus Calmette-Guérin therapy for bladder cancer. Eur Urol (1989) 0.96

Male pattern baldness and the risk of prostate cancer. Ann Oncol (2011) 0.90

[Testicular implants, patient's and partner's satisfaction: a questionnaire-based study of men after orchidectomy]. Prog Urol (2008) 0.90

Systemic complications of intravesical BCG therapy for bladder cancer. Lancet (1985) 0.89

Intermittent androgen suppression in patients with prostate cancer. BJU Int (2003) 0.89

[Place of nephrectomy in patients with autosomal dominant polycystic kidney disease waiting for renal transplantation]. Prog Urol (2008) 0.88

IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol Lett (1997) 0.87

Identification of p53 peptides recognized by CD8(+) T lymphocytes from patients with bladder cancer. Hum Immunol (2001) 0.86

[Circumstances of the detection of kidney cancer. Current part of accidental discoveries]. J Urol (Paris) (1994) 0.86

Proinflammatory and antitumor properties of interleukin-18 in the gastrointestinal tract. Immunol Lett (2000) 0.85

Corporeal plication for surgical correction of penile curvature. Experience with 60 patients. Eur Urol (1998) 0.84

Color Doppler-guided prostate biopsies in 591 patients with an elevated serum PSA level: impact on Gleason score for nonpalpable lesions. Urology (1997) 0.84

Image based renal stone tracking to improve efficacy in extracorporeal lithotripsy. J Urol (1998) 0.84

Analysis of interleukin-18, interleukin-1 converting enzyme (ICE) and interleukin-18-related cytokines in Crohn's disease lesions. Eur Cytokine Netw (2001) 0.84

[Primary metastatic urethral melanoma: a case study]. Prog Urol (2009) 0.83

[Retroperitoneal benign schwannoma]. J Urol (Paris) (1993) 0.83

Homelessness and high-dosage buprenorphine misuse. Subst Use Misuse (2003) 0.83

Hepatitis B vaccination in women healthcare workers: a seroepidemiological survey. Eur J Epidemiol (2007) 0.83

BCG therapy in superficial bladder tumours--complications and precautions. Eur Urol (1992) 0.83

Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer. Prog Clin Biol Res (1989) 0.82

p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors. J Urol (1998) 0.82

[Use of double J ureteral stent as an alternative to prevent ureteroileal anastomosis stricture in orthotopic bladder substitution]. Prog Urol (2008) 0.82

ICSI outcomes in obstructive azoospermia: influence of the origin of surgically retrieved spermatozoa and the cause of obstruction. Hum Reprod (2005) 0.82

[Epidermoid cyst of the testis. Apropos of a case]. J Urol (Paris) (1994) 0.81

[Iodin 125 seed migration after prostate brachytherapy: a study of 170 patients]. Cancer Radiother (2004) 0.81

Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases. Urology (1997) 0.81

Predictive factors of radiation therapy for patients with prostate specific antigen recurrence after radical prostatectomy. BJU Int (2002) 0.80

[Chromophobe cell renal cancer, a distinct entity. Report of a series of 35 cases]. Prog Urol (2001) 0.80

Local immunostimulation induced by intravesical administration of autologous interferon-gamma-activated macrophages in patients with superficial bladder cancer. Clin Exp Immunol (2002) 0.80

Endoscopic ureteroneocystostomy: palliative urinary diversion in advanced prostatic cancer. Tech Urol (1998) 0.80

Genitourinary tumors and HIV1 infection. Eur Urol (1990) 0.80

[Surgical treatment of urethral diverticula. Retrospective critical study: value of surgery in the ventral-decubital position]. Ann Urol (Paris) (1989) 0.79

[Brachytherapy in the curative treatment of localized prostatic cancer]. Prog Urol (2000) 0.79

Endorectal color doppler sonography and endorectal MR imaging features of nonpalpable prostate cancer: correlation with radical prostatectomy findings. AJR Am J Roentgenol (2000) 0.79

Venous thromboembolism in medical inpatients: prophylaxis with low-weight heparin in a university hospital and prevalence of thromboembolic events. Clin Appl Thromb Hemost (2001) 0.79

Molecular diagnosis of congenital bilateral absence of the vas deferens: analyses of the CFTR gene in 64 French patients. Ann Genet (1997) 0.78

[Severe algoneurodystrophy of the right foot associated with prostatic cancer]. J Urol (Paris) (1996) 0.78

[Urogenital tuberculosis : current status and future perspectives (author's transl)]. Sem Hop (1982) 0.77

[Association of angiomyolipoma and oncocytoma of the kidney. Apropos of two cases]. J Urol (Paris) (1993) 0.77

[PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure]. Cancer Radiother (2006) 0.77

[Helicobacter pylori infection in children of developing countries]. Med Trop (Mars) (2005) 0.77

[Permanent implant prostate cancer brachytherapy]. Cancer Radiother (2008) 0.77

[Hypertension and Cushing's disease]. Ann Med Interne (Paris) (1983) 0.76

[Cystine lithiasis: study of a series of 116 cases]. Prog Urol (2000) 0.76

[Brachytherapy for prostate cancer: old concept, new techniques]. Bull Cancer (2006) 0.76

[Cellular or atypical mesoblastic nephroma of partially cystic form. Apropos of a case in a 27 year old woman]. J Urol (Paris) (1992) 0.75

[Results of endorectal MRI in local staging of prostatic cancer. Correlation with specimens from prostatectomy. Apropos of 47 cases]. J Urol (Paris) (1996) 0.75

Delayed nonurothelial metastatic lesions to the penis: a report of two cases. Eur Urol (1989) 0.75

[Prostatic adenocarcinoma: pathological stage C. I: Diagnosis, technical aspects and significance]. J Urol (Paris) (1991) 0.75

[A new therapeutic approach to urogenital tuberculosis]. Sem Hop (1983) 0.75

[Treatment of urinary stress incontinence in women by percutaneous cervico-cystopexy. Gitte's operation: contribution of intraoperative ultrasonography. Apropos of 47 patients]. J Urol (Paris) (1992) 0.75

[Extracorporeal lithotripsy as the primary procedure in the treatment of large kidney calculi]. Ann Urol (Paris) (1988) 0.75

[Infiltrating bladder tumor. Urinary diversion and stoma therapy]. Soins Chir (1992) 0.75

[Chronic lymphocytic leukemia and cystadenocarcinoma of the kidney. A report of one case (author's transl)]. Sem Hop (1980) 0.75

[Epidermoid carcinoma of the bladder. Apropos of 46 cases]. Ann Urol (Paris) (1987) 0.75

[TIL (tumor-infiltrating lymphocytes): a new therapeutic approach for metastasizing kidney cancer]. Rev Med Suisse Romande (1992) 0.75

[Laryngeal pseudotumor related to BCGitis]. Presse Med (1992) 0.75

[Long ureteral ammonium-magnesium phosphate (struvite) and calcium phospho-carbonate calculi]. J Urol (Paris) (1991) 0.75

[Treatment of calculi of the lumbar ureter. Apropos of a series of 118 patients]. J Urol (Paris) (1991) 0.75

[Localized transrectal hyperthermia in the treatment of obstructive manifestations of prostatic adenoma. Review of the literature and personal experience]. J Urol (Paris) (1992) 0.75

[Conservative treatment of a recurring retroperitoneal liposarcoma. Apropos of a case followed over 27 years]. J Urol (Paris) (1991) 0.75

[Treatment of epidermoid carcinoma of the penis]. Presse Med (1989) 0.75

[Detection of a prostatic adenocarcinoma in the cysto-prostatectomy specimens of an invasive tumor of the bladder]. Ann Urol (Paris) (1989) 0.75

[Testicular tumor and male pseudohermaphroditism due to absence of MIF (Müller inhibiting factor)]. Ann Urol (Paris) (1987) 0.75

[Treatment of ureteral calculi by ureteroscopy and intra-corporeal lithotripsy]. Chirurgie (1991) 0.75

[Renal angiomyolipoma. Diagnostic value of magnetic resonance imaging]. Presse Med (1988) 0.75

[Morbidity of radical prostatectomy for localized cancer of the prostate. Apropos of 100 cases]. J Urol (Paris) (1992) 0.75

[Papillary cystadenocarcinomas of the kidney]. Sem Hop (1981) 0.75

[Adenocarcinoma of the prostate: pathological stage C. 2: Treatment]. J Urol (Paris) (1991) 0.75